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Anorexia nervosa (AN) is a psychiatric illness characterized by a lack of motiva-
tion and a taste for rewarding food consumption. Mood disorders such as depression 
and stress are frequently associated with this condition. Abnormalities in several 
neural systems have been identified in patients with AN, including serotonin, 
dopamine (DA), appetite-related neuropeptides, and other neurochemical systems. 
Moreover, the changes that occur between the mesolimbic dopaminergic pathway 
and the orexin neurons in the lateral hypothalamus (LH) in response to the reduction 
in food consumption are key in the development of AN. Several studies suggest a 
functional relationship between orexin and dopaminergic circuits. LH orexin neurons 
project dense fibers on dopaminergic neurons, potently activating these neurons. DA 
and orexin neurons regulate negative and positive motivational states, such as drug 
and food seeking behavior. For this reason, it is important to extend the study of the 
functional and emotional interactions that exist between both neuronal systems to 
design new drugs that act at a behavioral and molecular level to treat AN. This chapter 
provides an overview of the evidence from literature implicating dopamine-orexin 
systems in AN and discusses recent advances that have contributed to our current 
understanding of the mechanisms underlying the molecular bases of AN.
Keywords: mesocorticolimbic system, dopamine receptors, reward, mental illness, 
orexin neurons, motivation, anxiety disorders
1. Introduction
Anorexia nervosa (AN) has been classified as a chronic psychiatric disease since 
this condition has a strong emotional component. AN belongs to a group of eat-
ing disorders and is characterized by extreme body weight loss. AN patients show 
combination of physical, psychological, and behavioral disturbances that usually 
have their onset during adolescence. AN is associated with high levels of psychi-
atric comorbidity including psychosis, hyperactivity, depression, and anxiety. In 
consequence, this illness has become a major focus of attention in terms of both the 
research community and the general public. The prevalence of AN is approximately 
1% in women and less than 0.5% in men [1]. Patients with AN show a high degree 
of anhedonia (the reduced capacity to experience reward or pleasure) and have a 
disturbed body image and an intense fear of weight gain. Standardized mortality 
ratios show that the rate of death in AN is at least five times greater than that in the 
general population [2].
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Little is known about the etiology and the intrinsic biological alterations of 
anorexia, but it appears to be the result of different factors, for example, low 
self-esteem, certain personality traits such as perfectionism, mental illnesses such 
as depression, anxiety, self-harm, difficulty to manage stress and cope with life. 
Feelings of obsession and compulsion are also related with AN. Society and com-
munication media play a key role in this pathology, since through them we are 
constantly told that the image of the body is very important because it reflects our 
value, as people. While culture, society, and the media exert pressure on women to 
remain thin, now it is widely accepted that there is a biological basis for this psy-
chiatric disorder. Henceforth, the complexity of AN has limited the development 
of neuroscience-based treatments, and no medication or other biological treatment 
has been approved for the disorder. Then, to understand the biology of pathological 
eating behavior is an important step in the development of appropriate pharmaco-
therapies that can be used to treat AN patients.
To date abnormalities in several neural systems have been identified in patients 
with AN, including serotonin and DA, appetite-related neuropeptides, and other 
neurochemical systems. This chapter will focus especially on the dopaminergic 
neurons of the ventral tegmental area (VTA) that project the nucleus accumbens 
(NAc) to form the mesocorticolimbic circuit; and in the orexin neurons localized 
exclusively in two subregions of the hypothalamus; the perifornical area (PFA) and 
the LH, where orexin peptide is expressing [3].
Previously, it was thought that the serotonin system was the only or most 
important neurotransmitter involved in AN, and all research was carried out 
around its neurotransmission. Subsequently, preclinic and clinic evidence propose 
that the dopaminergic system could be a key factor in the pathophysiology of eating 
disorders. The AN is characterized by a reduction in food intake (diet restriction) 
and hyperactivity. In this sense, decrease in DA content has been observed in hypo-
thalamus, hippocampus, and the dorsal striatum after a restricted diet. Moreover, 
the motor activity is modulated mainly by dopaminergic circuits. These first data 
point out for the first time the possible contribution of dopaminergic transmission 
in anorexia.
The signals to eat or to stop eating are very complex and extend beyond the 
control of the homeostatic system that responds to metabolic and satiety signals 
from the gut. Recently, it has been proposed that mesocorticolimbic dopaminer-
gic system also responds to features of food such as the sight, smell, and taste in 
addition to cues that predict food intake and override the ingestive behavior [4]. 
The motivation to eat is key in eating behavior and is regulated by several intrinsic 
and extrinsic factors. Neuronal and circulating peptides are released in response of 
internal states, such as hunger or satiety, to stimulate or repress food intake, respec-
tively. Accumulating evidence has pointing out the orexin-containing neurons as 
central regulators of feeding behavior, energy balance modulation, and metabolic 
homeostasis.
2. Dopamine neurons
DA is a catecholamine and is a key neuromodulator involved in motivated 
behaviors. DA-containing neurons are characterized by the presence of tyrosine 
hydroxylase (TH), the rate-limiting enzyme in the synthesis of catecholamines, and 
are found throughout the mammalian central nervous system (CNS), including the 
ventral midbrain (VM) [5]. Midbrain DA-containing neurons are arranged princi-
pally in two nucleus: the substantia nigra pars compacta (SNc, also known as the A9 
group) and the VTA, or A10 group [5, 6]. Different populations of DA-containing 
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neurons project to distinct areas and control or modulate specific functions, 
according to their targets. We will emphasize in the VTA nucleus, which project 
to ventromedial striatum (NAc) and PFC, forming the mesocorticolimbic system. 
These DA-containing neurons regulate emotional behavior, natural motivation, 
reward and cognitive function, and are largely implicated in a range of psychiatric 
disorders [7–9].
DA acts primly through of two G protein-coupled DA D1 (D1R) and D2 (D2R) 
receptors [10]. D1R is a postsynaptic receptor that mediates more directly behavior, 
and the D2R is a presynaptic autoreceptor that regulates DA release in a negative 
feedback fashion; D1R increases, whereas D2R decreases adenylyl-cyclase activity, 
and both receptor types are distributed throughout the CNS [11]. A variety of stud-
ies indicate that an altered DA function in AN could be implicated. Patients with 
AN have shown low levels of homovanillic acid in their cerebrospinal fluid (CSF), 
the major DA metabolite [12]; in addition, a positron emission tomography (PET) 
study revealed an increase in D2R binding in the anteroventral striatum (NAc in 
rodents), in a mixed group of women recovered from both restricted-type anorexia 
nervosa and binge-eating/purging-type [13]. These data suggest that neuronal or 
synaptic DA may be reduced, but that DA receptors could be increased in number 
or sensitivity in a compensatory or negative feedback fashion [14]. Thus, a down-
regulation of receptor sensitivity might be an important therapeutic goal in AN, to 
compensate the low levels of DA.
Several hypotheses have been raised about the contribution of DA in AN. On 
one side, Bergh and Södersten [15] suggest that normal DA responses to hunger and 
exercise facilitate a progression into AN; in addition, O’Hara et al. [16] proposed 
that an anomaly in the reward system mediated by the DA leads to the development, 
maintenance, and resistance to the treatment of the AN.
2.1  Mesocorticolimbic dopamine neurons may facilitate the development of 
anorexia nervosa
According to Bergh and Södersten [15], dieting, along with high levels of exer-
cise, leads to a stress response that increases cortisol and corticotrophin-releasing 
factor (CRF) [17–22], which in turn promotes an increase in DA levels in the NAc 
[23, 24]. In such a way, DA facilitates rewarding behaviors such as diet and exercise to 
become habits similar to those associated with drug dependency or self- starvation by 
conditioning this type of reward to initially neutral stimuli [15, 25–28]. In addition, 
the high CRF levels induced by diet restriction and exercise also facilitate to seek for 
food, while simultaneously suppressing food intake [29]. However, until now there 
is no clinical study that compares the DA levels in anorexic subjects before and after 
developing anorexia that shows chronically high levels of DA before the disease was 
declared.
2.2 Aberrant concept of starvation in anorexia nervosa
The mentalistic concept of AN assumes that it results from a mental illness. This 
concept describes this illness as a set of chronic and serious mental disorders with 
debilitating physical, cognitive, and socioemotional impairments such as anxiety, 
depression, obsessional traits, and pathological cognitions. Therefore, when the 
initial care of a patient with anorexia is focused only on cognitive therapies to 
treat psychological disorders do not usually give good long-time results. Moreover, 
symptoms such as anxiety and depression also emerge in healthy people during a 
starvation period [30]. There are many arguments against the hypothesis that an 
underlying mental disorder causes AN [31]. Recently, it was discovered that AN 
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and anxiety have different genetic risk factors. Also, almost all mental disorder 
symptoms observed in anorexics disappear after normalization of eating behavior 
[31, 32].
O’Hara et al. [16] do not agree with the mentalist concept because this does not 
assume the normal functions of the neuroendocrine system, which is responsible 
for regulating the release of peptides that regulate food consumption. The mentalist 
concept does not take into account the physiological aspects in eating disorders, and 
this may be the reason why this approach to treating anorexia as a consequence of a 
mental illness has not led to an effective treatment. O’Hara et al. [16] proposed that 
an abnormality in the reward system mediated by DA leads to the development, 
maintenance, and resistance to treatment in the AN.
They suggest that the decrease in dopaminergic activity and the rejection of food 
intake are key in the development of anorexia. Therefore, they propose increas-
ing DA levels to normalize the consumption of food to reduce the stress generated 
by starvation, which in turn reduces the release of CRF to gradually increase the 
consumption of food. However, recent studies suggest that changes in DA found 
in anorexic patients are due more to a normal characteristic of starvation than to a 
disease marker.
3. Hypothalamic orexin neurons modulate dopaminergic neurons
Orexin-A and orexin-B neuropeptides were initially identified as endogenous 
ligands for two orphan G protein-coupled receptors; the OX1R is coupled entirely to 
Gq, whereas OX2R is coupled to both Gi/o and Gq [33]. Both orexins are derived from 
proteolytic cleavage, of a precursor peptide (pre-pro-orexin), and are produced by a 
group of neurons in the LH and PFA, a region known as the feeding center (Figure 1). 
OX-A has the same affinity with both receptors, while OX-B has a greater affinity for 
OX2R than OX1R [33, 34]. These receptors are highly expressed throughout the brain 
including the “dopaminergic reward pathways” (Figure 1) [35–39]. Moreover, these 
Figure 1. 
Schematic representation of the brain areas related to motivated and emotional behaviors. (A) Coronal section 
of the rat brain showing the lateral (LH) and perifornical area (PEA) of hypothalamus. (B) Representation 
of the main orexin projections and the expression of orexin receptors 1 and 2 (OX1R and OX2R) in these 
brain regions. The fear circuit comprising the hippocampus (Hypp), medial prefrontal cortex (mPFC), and 
amygdala (AMY). Areas implicated in anxiety: bed of the stria terminals (BNST), paraventricular thalamus 
(PVT), and septum. The paraventricular nucleus of the hypothalamus (PVN) regulates stress responses 
and the hypothalamic-pituitary-adrenal axis hormone cascade. The mesocorticolimbic system modulates 
the rewarding properties of food and drugs of abuse and comprising the ventral tegmental area (VTA) and 
nucleus accumbens (NAc). The locus coeruleus (LC) also has dense orexin innervations in concordance with its 
involvement in arousal and emotional memory. Abbreviation: LH, lateral hypothalamus.
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peptides are also regarded as an important factor that regulates feeding behavior, 
owing to their localization within the lateral hypothalamic area, the classic “feeding 
center.”
Orexins were recognized as positive regulators of energy expenditure, thanks to 
the development of the orexin neuron-deficient mice. Studies conducted in these 
animals led to propose that orexins promote acute food consumption on one hand 
and on the other hand prevent the progress of obesity [40]. Since then, numerous 
pharmacological and genetic studies have supported that these peptides together 
with their receptors are key regulators of energy expenditure, thus influencing the 
energy balance.
The activation of the orexin system by means of the microinjection of orexin-A in 
the hypothalamus has shown that these peptides act as protectors in the development 
of obesity, by increasing energy expenditure. Also, orexin neurons increase energy 
expenditure by increasing thermogenesis in brown adipose tissue [40]. On the other 
hand, it has been observed that overexoression of pre-pro-orexin gene in an animal 
model promotes resistance to obesity induced by consumption of a high-fat diet [41]
The available anatomical, genetic, and pharmacological evidence supports that 
the behavioral consequences of the activity of the orexin system are due to parallel 
signaling to multiple brain regions and neurotransmitter systems such as DA. For 
example, the NAc is involved in hedonic and motivational aspects of feeding 
[42] and is an important brain region because endogenous orexin peptides act to 
modulate DA release [43], which act over hedonic processes associated with food 
evaluation and consumption. In addition, NAc is involved in the reward of natural 
behaviors, such as exercise, sex, and, of course food intake.
Orexins in the VTA, the major dopaminergic nucleus, have been implicated 
in drug and alcohol seeking and reinstatement. as well as food seeking, in highly 
salient circumstances, food seeking in highly salient circumstances, for example, 
during hunger, presentation of palatable foods or with exposure to food-related 
cues, but not in the consumption of regular food [44, 45]. An alternative mecha-
nism by which orexins can stimulate the consumption of highly palatable food 
is via the paraventricular thalamic nucleus (PVT) because orexin neurons in 
the hypothalamus also send dense projections to the PVT [37], which in turn 
regulates DA efflux to the NAc via its glutamatergic projections [46, 47]. It has 
been reported that orexin actions in PVT promote DA efflux in the NAc, while 
the inhibition of its receptor OX1R in this region decreases hedonic intake of 
palatable foods [48]. Therefore, orexins not only can act directly in the VTA to 
increase DA [45, 49] but they also increase DA via action in the PVT to promote 
hedonic food intake [48]. In summary, the control that orexins exert over VTA-
NAc circuit is key to modulate motivational behaviors and reward processes 
related to drug, alcohol, and food seeking.
Functional studies show the relationship between LH orexins and VTA-NAc 
circuit where orexins exert their actions on the dopaminergic neurons by increasing 
the firing frequency in VTA neurons in vitro and in vivo [50, 51]. These peptides 
induce an increase in DA release and its metabolites in both NAc and PFC [4, 49, 
52, 53]. Electrical stimulation of the LH nucleus can increase both food intake and 
accumbal DA turnover [54–56]. In contrast, the inhibition of OX1R reduces DA cells 
firing [57], as well as significantly decrease in amphetamine, and cocaine-induced 
DA release in the NAc [57, 58]. On the other hand, the intracerebroventricular 
administration of OX-A leads to stress-related behavior like grooming, stereotypy, 
and hyperlocomotion [59], actions that were inhibited by DA D1 receptor (D1R) 
or DA D2 receptor (D2R) antagonists in rodents [59]. These data provide strong 
evidence that the orexin system contributes to DAergic neurons regulation in the 
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mesocorticolimbic pathway and that the action of orexins in these neurons could 
involve a variety of behaviors that are known to be regulated by DA.
This framework suggests that understanding the function of the orexin requires 
studying them in a brain region-specific basis, as well as understanding the interac-
tions between different brain regions that receive orexinergic input [40]
4. Anorexia nervosa and anxiety disorders: role of orexin and dopamine
4.1 Anorexia nervosa and anxiety disorders
AN is a very complex disease, characterized by a profound dysregulation in 
neurocircuits related to control eating behavior, anxiety, fear, and reward positive/
negative reinforcers. AN is a serious motivated behavioral condition with high mor-
bidity and mortality. Anorexic patients usually have a high comorbidity with severe 
anxiety disorders, such as obsessive-compulsive disorder (OCD) and social anxiety 
disorder (SAD) [60]. One characteristic that anorexics share with people suffering 
from SAD is their fear and concern about how other people perceive them. Elevated 
neuroticism and perfectionism as well as decreased novelty seeking are anxious 
personality traits observed in these disorders [60]. Therefore, anxiety disorders 
and AN are strongly correlated; in both disorders, the fear is organized around an 
irrational belief associated with heightened vigilance and pronounced anxiety. 
Another characteristic shared between AN and OCD is compulsivity: to engage in 
repetitive and stereotyped acts that have unwanted outcomes [61] and arises from 
a reduced ability to control inflexible yet maladaptive behavior as the starvation, 
which persists in the face of negative consequences, for example, interfering with 
academic/occupational/social interests in longer term and the behaviors promoting 
further, and potentially dangerous, weight loss.
Recently, Lloyd et al. [62] have proposed a central role for anxiety in the devel-
opment of compulsive starvation; they suggest a dual mechanism by which anxiety 
could be motivating the initiation of AN and propose that the reinforcement effects 
of starvation cause excessive repetition of behaviors leading to the buildout of 
psychological symptoms of AN. They also suggest that starvation becomes com-
pulsive until it has adverse implications for anxiety, which generates the symptoms 
of AN and which encourages the formation of a vicious circle that guarantees the 
persistence of an extreme dietary restriction. Stress and distress tolerance have been 
suggested as important factors in determining the onset and course of AN [61]. 
Stressful and traumatic events often precede eating diseases. Notably, high levels of 
anxiety tend to also precede the onset of addiction and OCD.
Dietary restriction has an anxiolytic effect, because women recovered from AN 
show elevated levels of serotonin (5-HT) metabolites [63], and gene variants linked 
to more active 5-HT and noradrenaline (NA) systems are implicated in AN [64, 65], 
supporting the involvement of these neurotransmitter systems in the heightened 
anxiety that precedes AN. Thus, dietary restriction relieves the anxiety (or negative 
reinforcement) provided by the dietary restriction that increases with anxiety.
Starvation is a compulsive behavior that over time becomes a habit with a 
dominant influence in individuals with AN. Surprisingly, in anorexics, there is an 
imperative need to keep starving [62]. However, this behavior puts your life at risk.
Subjects with AN show an extreme aversive state characterized by high levels of 
anxiety when eating, that is, when they do not carry out their compulsive behavior 
of starvation [61, 66]. This is also observed in addiction and OCD, where the execu-
tion of compulsions serves to temporarily relieve the negative effects [61, 67–69]. 
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Several studies indicate that the levels of anxiety in anorexics are even higher than 
before the restriction of food and that this anxious behavior is partially mediated 
by an increased sensitivity of the 5-HT and NA systems, which results from the 
reduced consumption of tryptophan and tyrosine, respectively [70, 71].
When starvation becomes necessary to avoid an extremely anxious state, 
the desire to starve is enhanced given the poor emotion regulation abilities of 
individuals with AN, which limits the use of alternative strategies to overcome 
dysphoria [72–74].
Anxiety precedes and coincides with restrictive eating in AN [75–78], which 
is not the case for individuals without the disorder [77]. Repeatedly engaging in 
dietary restriction in an anxious state facilitates anxiety to evoke restrictive eating 
habits, due to a pairing of emotion and behavior.
Thus, several mechanisms likely explain how anxiety promotes engagement 
in maladaptive dietary restriction habits that have developed during a compulsive 
illness.
4.2 Dopamine and orexins systems: evidence for an interconnection in anorexia 
nervosa
Stress and distress tolerance have been suggested as important factors in deter-
mining the onset and course of AN. Stressful and traumatic events often precede 
eating diseases. AN comprises a hyperactivation of the HPA axis [79]. Patients 
with AN present significantly elevated concentration of plasma cortisol, increased 
central CRF, and significantly less cortisol suppression after dexamethasone 
administration than controls [80, 81]. Moreover, hormonal changes also do not 
seem to be specific for AN and are found in other diseases or in healthy subjects as 
a consequence of malnutrition and starvation [82]. In general, these data show the 
need to study other molecules as possible indicators of HPA-axis hyperactivity on 
the one hand and that regulate emotional states on the other hand. DA and orexins 
share diverse characteristics at the physiological, psychological, and psychiatric 
levels, such as the ability to modulate the HPA axis activity, induce drug and food 
seeking behavior, increase the motivation to obtain food, and regulate emotional 
states, such as depression and anxiety.
At first it was thought that orexins participated in the consumption of food 
because orexin central administration produces food seeking, and food depriva-
tion increases orexin mRNA [83, 84]. In addition, orexin neurons are excited by 
peripheral signals of nutrient needs (e.g., ghrelin), inhibited by satiety signals (e.g., 
glucose) and interact with feeding peptides to promote food consumption and seek-
ing [85–89]. Notably, orexin neurons are active during hunger and help to translate 
peripheral hunger signals into increased appetitive responding for food and cues 
associated to consumption of food. Thus, orexins facilitate food seeking especially 
in motivationally charged circumstances.
Orexins orchestrate various aspects of stress responses. For example, acute (but 
not chronic and predictable) stress is associated with orexin neuron activation 
[90]. The orexins help to organize the response to stress, but only when it assumes a 
motivated and adaptable behavior to cope with stress, that is, when you can escape 
the stressor. In contrast, when a stressor is chronic, predictable, and impossible to 
escape, the activity of orexin system decreases, and this hypoactivity can produce 
motivational symptoms similar to depression.
In the case of DA, it is involved in motivational but not consummatory aspects 
of feeding. The blocking of mesocorticolimbic dopaminergic system decreases the 
response for motivational tasks associated with obtaining food [91]. DA depletion 
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or administration of DA receptor antagonists in NAc reduces the motivation to 
consumption high palatable food [92–95]. The motivation to eat is a key factor to 
maintain a normal feeding behavior.
Dysfunction of the OXs and DA systems may contribute to the pathology of 
anxiety and addiction to food and drugs of abuse, which is commonly associated 
with anxiety and/or defective fear processing, depression, and cognitive impair-
ment as well as other comorbid conditions. Increase in orexin mRNA levels has been 
observed in animals exposed to different stressors such as immobilization [96], cold 
stress [96], or hypoglycemia [84], while that both acute and chronic stress promote 
major changes in DA signaling in the mesocorticolimbic pathway such as increases 
in DA release in the striatum, NAc, and PFC [97–99]. D2R receptor knockout mice 
display anxiety and depression-like behaviors upon chronic stress [100]. Repeated 
restrain stress produces increases and decreases in DA receptor densities within the 
mesoaccumbens and nigrostriatal systems in two different strains of mice [101]. So, 
these results suggested that stressful conditions could be augmented the vulner-
ability to develop psychiatric illnesses as AN. So, any decline in the transmission of 
DA and orexins can generate a lack of motivation to consume food. However, there 
are few studies about the participation of DA receptors in the PFA/HL areas on the 
control of food drinking. Studies suggest that ethanol intake and excessive food 
consumption could be similarly affected by DA in the PFA/HL areas, with increases 
in both ethanol and food intake after D1 receptor activation and decrease in both 
consumptions after the activation of D2 [100].
Considering that the anxiety induces specific reduction of the D2R in the NAc 
and that DA attenuates several addictive behaviors in animals [100], it is difficult 
not to think that DA may act as an anxiolytic agent through the D2R activation. 
On the other hand, the decreased release of orexins could promote low food 
consumption, that is, the dysfunction of the orexin system could be accentuating 
the lack of motivation for the search and consumption of food in anorexics. In this 
way, the stimulation of orexin receptors together with DA could reduce the stress 
generated by starvation and, at the same time, increase the motivation for food 
consumption.
5. Conclusion
Considering on the one hand that AN is a compulsive disorder, and on the 
other hand that starvation is the result of a negative reinforcement, it is suggested 
that the dysfunction of DA and orexins in the mesocorticolimbic system is key 
to the successful treatment of AN. The model can justify the use of existing and 
planned prevention and treatment programs but may also guide the development of 
novel interventions to favorably affect the incidence and recovery rates of a life-
threatening condition.
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